CK19, Hep-Par 1, and CEA are nonetheless essential to establish a diagnosis.3 The study by Su et al3 suggests that new immunohistochemistry markers may be useful to differentiate HAC from HCC. This evidence concerns the gene KRT19 and hepatocellular carcinoma.